Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
6.64 (USD) • At close November 4, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Recursion Pharmaceuticals, Inc. |
Symbool | RXRX |
Munteenheid | USD |
Prijs | 6.64 |
Beurswaarde | 1,887,028,240 |
Dividendpercentage | 0% |
52-weken bereik | 5.035 - 15.74 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Christopher C. Gibson Ph.D. |
Website | https://www.recursion.com |
An error occurred while fetching data.
Over Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)